Broadcast Two

Taking Management of Primary Biliary Cholangitis to the Next Level: A Focus on Early Recognition, Long-term Disease Monitoring and Novel Treatments to Improve
Real-World Outcomes




Liver Institute Northwest

Professor of Medicine

Elson S. Floyd College of Medicine

Washington State University

Pullman, WA

Raj Vuppalanchi, MD, FAASLD

Professor of Medicine

Indiana University School of Medicine


Indiana University Health

Indianapolis, IN

Sonal Kumar, MD, MPH

Assistant Professor of Medicine

Weil Cornell Medical College

Cornell University

Program Overview

Primary biliary cholangitis (PBC) a chronic and progressive autoimmune liver disease that can lead to cirrhosis if unrecognized and untreated. In this educational activity, PBC experts will address knowledge and competence barriers related to disease pathophysiology, early recognition and diagnosis, long-term disease monitoring, and pharmacologic treatment. Clinical practice guidelines and approved and emerging therapies will be explored. A focus of the program will be second-line therapies and how that appropriate advancement through the treatment pathways may improve real-world outcomes.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Formulate care pathways for long-term disease monitoring in patients with PBC
  • Evaluate recent guidelines and real-world data for approved and emerging therapies for PBC


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium Continuing Education (Iridium). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 0.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the broadcast
  • Complete the posttest with a score of 70% or higher

A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or


Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Consulting Fee (e.g., Advisory Board): CymaBay, Corcept, Genfit, GSK, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pliant, Pfizer, 89bio, Zydus
Contracted Research: Boston, Corcept, CymaBay, Genfit, GSK, Hanmi, Intercept, Ipsen, Janssen, Madrigal, Mirum, Novo Nordisk, NGM, Pfizer, Plaint, Terns, Viking, 89bio, Zydus
Speakers' Bureau: Abbvie, Gilead, Intercept
Stock Option Holder: Inipharm, Royalty
Sonal Kumar, MD, MPH
Consulting Fee (e.g., Advisory Board): Gilead Sciences, Intercept Pharmaceuticals, Ipsen
Contracted Research: Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, CymaBay Therapeutics, Galectin Therapeutics, Inventiva Pharma, Madrigal Pharmaceuticals, Genfit
Honoraria: Gilead Sciences, Intercept Pharmaceuticals, Novo Nordisk, Ipsen
Speakers' Bureau: Gilead Sciences, Intercept Pharmaceuticals
Raj Vuppalanchi, MD, FAASLD has no relevant financial relationships with ineligible companies to disclose.
The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This educational activity is supported by an educational grant from Intercept Pharmaceuticals, Inc.

Credit Amount: 0.50
Credit Type: AMA
Release: June 28, 2023
Expiration: June 28, 2024